title: Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
abstract: The objective of this study was to investigate the relationship between the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) and the response to capecitabine in patients with advanced/recurrent gastric cancer. TP and DPD expression in paraffin-embedded specimens of primary lesions, obtained from 25 patients before capecitabine chemotherapy, were evaluated by immunohistochemical staining with anti-TP and anti-DPD monoclonal antibodies. The patients (19 male and six female) had a median age of 65 years (range 37-74). All had a good performance status [Eastern Cooperative Oncology Group (ECOG) 0 or 1]. Overall response rate to capecitabine therapy was 32%. TP was positive in 19 tumors (76%) and DPD was positive in 13 tumors (52%). The response rate (RR) was significantly higher (Fisher's exact test, P=0.028) in patients with TP-positive and DPD-negative tumors (RR=60%, 6/10) than in the remaining patients (RR=13%, 2/15). TP and DPD expression profiles are useful for predicting a response to capecitabine.
authors.affiliation: Department of Gastroenterology, East Hospital, Kitasato University School of Medicine, Sagamihara City, Kanagawa, Japan. koizumi@med.kitasato-u.ac.jp
authors.forename: Wasaburo
authors.initials: W
authors.lastname: Koizumi
authors.forename: Isao
authors.initials: I
authors.lastname: Okayasu
authors.forename: Ichinosuke
authors.initials: I
authors.lastname: Hyodo
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kojima
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D016612:Paraffin Embedding; D011237:Predictive Value of Tests; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D017154:Stromal Cells / Q000201:enzymology / Q000473:pathology; D013939:Thymidine Phosphorylase / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D042943:Dihydrouracil Dehydrogenase (NADP); D013939:Thymidine Phosphorylase; D005472:Fluorouracil